# Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

> **NCT01470456** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 50 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** SAR3419
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT01470456
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-07
- **Final completion:** 2014-09
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2014-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470456, "Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01470456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*